Ganetespib
ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Synta Pharmaceuticals Corp.Small moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
trx518 Leap Therapeutics, Inc. | Phase 1 | CC |
ag-01 compound A&G Pharmaceutical Inc. | Phase 1 | CC |
Cyclophosphamide Leap Therapeutics, Inc. | Phase 1 | CC |
Avelumab Leap Therapeutics, Inc. | Phase 1 | CC |
FULVESTRANT Fudan University | N/A | D |
Palbociclib Fudan University | N/A | D |
Rapamycin Fudan University | N/A | D |
Same molecule, other indications
Ganetespib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →